Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

The overexpression of p16 is not a surrogate marker for high-risk human papilloma virus genotypes and predicts clinical outcomes for vulvar cancer

Authors: Jacek J. Sznurkowski, Anton Żawrocki, Wojciech Biernat

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

We aimed to evaluate the correlation between p16ink4a-overexpression and high risk (hr)HPV-DNA in vulvar squamous cell carcinoma (vSCC) tumors as well as the impact of both biomarkers on the prognosis of vSCC patients.

Methods

PCR-detection of (hr)HPV-DNA and immunohistochemical staining for p16ink4a were conducted in 85 vSCC tumors. Survival analyses included the Kaplan–Meier method, log-rank test and Cox proportional hazards model.

Results

p16ink4a-overexpression and (hr)HPV-DNA were detected in 35 and 37 of the 85 tumors, respectively. Among the 35 p16ink4a-positive tumors, 10 lacked (hr)HPV-DNA (29 %). Among the 50 p16ink4a-negative tumors, (hr)HPV-DNA was detected in 12 cases (24 %). The median follow-up was 89.20 months (range 1.7–189.5 months). P16ink4a-overexpression, but not (hr)HPV-DNA positivity of the primary tumor, was correlated with prolonged overall survival (OS) (p = 0.009). P16ink4a-overexpression predicted a better response to radiotherapy (p < 0.001). Univariate analysis has demonstrated that age (p = 0.025), tumor grade (p = 0.001), lymph node metastasis (p < 0.001), FIGO stage (p < 0.001), p16ink4a-overexpression (p = 0.022), and adjuvant RTX (p < 0.001) were prognostic factors for OS. Multivariate analysis has demonstrated that lymph node metastasis (HR 1–2.74, 95 % CI 1.50–5.02, p = 0.019), tumor grade (HR 1–2.80, 95 % CI 1.33–5.90, p = 0.007) and p16ink4a-overexpression (HR 1–2.11, 95 % CI 1.13–3.95, p = 0.001) are independent prognostic factors.

Conclusion

The discovered overlap suggests the use of p16ink4a in combination with HPV-DNA detection as an ancillary test for future research and clinical studies in vSCC. The prognostic and predictive value of p16ink4a-overexpression should be tested in larger cohort studies.
Appendix
Available only for authorised users
Literature
1.
Beller U, Quinn MA, Benedet JL, et al. Carcinoma of the vulva. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95:S7–S27.CrossRefPubMed
2.
Del Pino M, Rodriguez-Carunchio L, Ordi J. Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma. Histopathology. 2013;62:161–75.CrossRefPubMed
3.
Hart WR. Vulvar intraepithelial neoplasia: historical aspects and current status. Int J Gynecol Pathol. 2001;20:16–30.CrossRefPubMed
4.
Santos M, Landolfi S, Olivella A, et al. p16 overexpression identifies HPV-positive vulvar squamous cell carcinomas. Am J Surg Pathol. 2006;30:1347–56.CrossRefPubMed
5.
de Sanjosé S, Alemany L, Ordi J, Tous S, Alejo M, Bigby SM, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer. 2013;49(16):3450–61.CrossRefPubMed
6.
Alonso I, Fusté V, del Pino M, et al. Does human papillomavirus infection imply a different prognosis in vulvar squamous cell carcinoma? Gynecol Oncol. 2011;122:509–14.CrossRefPubMed
7.
Sznurkowski JJ, Zawrocki A, Emerich J, Biernat W. Prognostic significance of CD4+ and CD8+ T cells infiltration within cancer cell nests in vulvar squamous cell carcinoma. Int J Gynecol Cancer. 2011;21:717–21.CrossRefPubMed
8.
Sznurkowski JJ, Zawrocki A, Emerich J, Sznurkowska K, Biernat W. Expression of indoleamine 2,3-dioxygenase predicts shorter survival in patients with vulvar squamous cell carcinoma (vSCC) not influencing on the recruitment of FOXP3-expressing regulatory T cells in cancer nests. Gynecol Oncol. 2011;122:307–12.CrossRefPubMed
9.
Pecorelli S, FIGO Committee on Gynecologic Oncology. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105:103–4.CrossRefPubMed
10.
Kleter B, van Doorn LJ, Ter SJ, et al. Novel shortfragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol. 1998;153:1731–9.CrossRefPubMedPubMedCentral
11.
Kleter B, van Doorn LJ, Schrauwen L, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol. 1999;37:2508–17.PubMedPubMedCentral
12.
Pinto AP, Signorello LB, Crum CP, et al. Squamous cell carcinoma of the vulva in Brazil: prognostic importance of host and viral variables. Gynecol Oncol. 1999;74:61–7.CrossRefPubMed
13.
van der Avoort I, Shirango H, Hoevenaars BM, et al. Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways. Int J Gynecol Pathol. 2006;25:22–9.CrossRefPubMed
14.
De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124(7):1626–36.CrossRefPubMed
15.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans International Agency for Research on Cancer. Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon, France: Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer; Distributed by WHO Press: 2007.
16.
LaPak KM, Burd CE. The molecular balancing act of p16(INK4a) in cancer and aging. Mol Cancer Res. 2014;12(2):167–83.CrossRefPubMed
17.
Gonzalez S, Serrano M. A new mechanism of inactivation of the INK4/ARF locus. Cell Cycle. 2006;5:1382–4.CrossRefPubMed
18.
Quint W, Jenkins D, Molijn A, Struijk L, van de Sandt M, Doorbar J, Mols J, Van Hoof C, Hardt K, Struyf F, Colau B. One virus, one lesion—individual components of CIN lesions contain a specific HPV type. J Pathol. 2012;227(1):62–71.CrossRefPubMed
19.
Pérez C, Castillo M, Alemany L, Tous S, Klaustermeier J, de Sanjose S, Velasco J. Evaluation of p16(INK4a) overexpression in a large series of cervical carcinomas: concordance with SPF10-LiPA25 PCR. Int J Gynecol Pathol. 2014;33(1):74–82.CrossRefPubMed
20.
Wendt M, Romanitan M, Näsman A, Dalianis T, Hammarstedt L, Marklund L, Ramqvist T, Munck-Wikland E. Presence of human papillomaviruses and p16 expression in hypopharyngeal cancer. Head Neck. 2014;36(1):107–12.CrossRefPubMed
21.
Kagie MJ, Kenter GG, Tollenaar RA, Hermans J, Trimbos JB, Fleuren GJ. p53 protein overexpression is common and independent of human papillomavirus infection in squamous cell carcinoma of the vulva. Cancer. 1997;80:1228–33.CrossRefPubMed
22.
Lindell G, Nasman A, Jonsson C, et al. Presence of human papillomavirus (HPV) in vulvar squamous cell carcinoma (VSCC) and sentinel node. Gynecol Oncol. 2010;117:312–6.CrossRefPubMed
23.
Ansink AC, Krul MR, De Weger RA, et al. Human papillomavirus, lichen sclerosus, and squamous cell carcinoma of the vulva: detection and prognostic significance. Gynecol Oncol. 1994;52:180–4.CrossRefPubMed
24.
Monk BJ, Burger RA, Lin F, Parham G, Vasilev SA, Wilczynski SP. Prognostic significance of human papillomavirus DNA in vulvar carcinoma. Obstet Gynecol. 1995;85:709–15.CrossRefPubMed
25.
Tringler B, Grimm C, Dudek G, et al. p16INK4a expression in invasive vulvar squamous cell carcinoma. Appl Immunohistochem Mol Morphol. 2007;15:279–83.CrossRefPubMed
26.
Reuschenbach M, Waterboer T, Wallin KL, Einenkel J, Dillner J, Hamsikova E, et al. Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers. Int J Cancer. 2008;123:2626–31.CrossRefPubMed
27.
Romagosa C, Simonetti S, López-Vicente L, Mazo A, Lleonart ME, Castellvi J, Ramon y Cajal S. p16Ink4a overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene. 2011;30:2087–97.CrossRefPubMed
28.
Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100:261–9.CrossRefPubMed
29.
Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol. 2009;27:1992–8.CrossRefPubMed
30.
Li W, Thompson CH, O’Brien CJ, et al. Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer. 2003;106:553–8.CrossRefPubMed
31.
Alos L, Moyano S, Nadal A, et al. Human papillomaviruses are identified in a subgroup of sinonasal squamous cell carcinomas with favorable outcome. Cancer. 2009;115:2701–9.CrossRefPubMed
32.
Cao F, Han H, Zhang F, et al. HPV infection in esophageal squamous cell carcinoma and its relationship to the prognosis of patients in northern China. Sci World J. 2014;2014:804738.
Metadata
Title
The overexpression of p16 is not a surrogate marker for high-risk human papilloma virus genotypes and predicts clinical outcomes for vulvar cancer
Authors
Jacek J. Sznurkowski
Anton Żawrocki
Wojciech Biernat
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2503-y

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Study protocol

Study protocol of the CHOiCE trial: a three-armed, randomized, controlled trial of home-based HPV self-sampling for non-participants in an organized cervical cancer screening program

Research article

Evaluation of serum and tissue levels of VAP-1 in colorectal cancer

Research article

Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review

Study protocol

A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme)

Case report

A germline mutation of CDKN2A and a novel RPLP1-C19MC fusion detected in a rare melanotic neuroectodermal tumor of infancy: a case report

Research article

L1CAM as a prognostic marker in stage I endometrial cancer: a validation study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits